EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Endogenous Ceramide 24:1 Constrains Th17‐Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling

Huan Liu, Abudureyimujiang Aili, Zheng Kuang, Liting Cao, Zemin Li, Ying Shang, Yingying Ge, Tingting Hu, Yongchang Sun, Wuli Zhao, Rong Jin, Chun Chang iD

Advanced Science · 2026

DOI: 10.1002/advs.202520695 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Huan Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Th17 Cells, Ceramides, Asthma, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Peking University Third Hospital's Cohort Construction Project, Key Clinical Projects of Peking University Third Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysregulated chronic inflammation underlies a spectrum of severe asthma phenotypes, among which neutrophilic asthma (NA) represents a treatment‐recalcitrant endotype characterized by Th17‐driven airway inflammation and steroid resistance. Although lipid mediators are known to play dual roles in promoting and resolving inflammation, the lipid species governing the Th17‐neutrophil axis in NA remain unknown. Here, through integrated lipidomic profiling of clinical samples (exhaled breath condensate, plasma, sputum) from an NA cohort and a murine model of Th17‐driven airway inflammation, a deficiency in very‐long‐chain ceramides, notably Cer24:1, was identified. This reduction correlated with disease severity and neutrophilic inflammation. In vivo, Cer24:1 supplementation alleviated airway hyperresponsiveness and neutrophilic infiltration, while Smpd1 knockout mice—with impaired ceramide generation—displayed exacerbated Th17 pathology. Using structure‐guided molecular docking, surface plasmon resonance, and functional assays, Cer24:1 was shown to directly target the prostaglandin E2 receptor EP2 on CD4 + T cells. This interaction suppressed JAK2–STAT3 signaling and RORγt‐driven Th17 differentiation. Notably, PGE 2 competitively reversed Cer24:1's protective effects, further supporting EP2‐dependent modulation. Our results reveal Cer24:1 as an endogenous pro‐resolving lipid that constrains neutrophilic inflammation via direct modulation of the EP2–STAT3 axis in Th17 cells, providing a new metabolic checkpoint and potential therapeutic strategy for severe neutrophilic asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Th17 CellsCeramidesAsthmaInflammationReceptors, Prostaglandin E, EP2 SubtypeNeutrophilsAnimalsMiceSignal TransductionHumansMice, KnockoutDisease Models, Animal

Stichwörter der Autor:innen

Th17 cellsceramideneutrophilic asthmasphingolipids

Substanzen

CeramidesReceptors, Prostaglandin E, EP2 Subtype

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China.
  • Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
  • Department of Immunology, Peking University Health Science Center, Peking University Center for Human Disease Genomics, Beijing, China.
  • State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of Antibiotic Bioengineering, Laboratory of Oncology, Institute of Medicinal Biotechnology, Ministry of Health, Chinese Academy of Medical Sc…
  • Department of Immunology, School of Basic Medical Sciences, Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, NHC Key Laboratory of Medical Immunology (Peking University), Peking…

ORCID-Profile: Chun Chang

Förderung

  • National Natural Science Foundation of China
  • Peking University Third Hospital's Cohort Construction Project
  • Key Clinical Projects of Peking University Third Hospital
  • Capital's Funds for Health Improvement and Research
  • State Key Laboratory Special Fund
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Liu, H., Aili, A., Kuang, Z., Cao, L., Li, Z., Shang, Y., Ge, Y., Hu, T., Sun, Y., Zhao, W., Jin, R., & Chang, C. (2026). Endogenous Ceramide 24:1 Constrains Th17‐Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling. Advanced Science. https://doi.org/10.1002/advs.202520695

Vancouver

Liu H, Aili A, Kuang Z, Cao L, Li Z, Shang Y, et al. Endogenous Ceramide 24:1 Constrains Th17‐Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling. Advanced Science. 2026. doi:10.1002/advs.202520695

BibTeX
@article{Liu2026,
  author = {Liu, Huan and Aili, Abudureyimujiang and Kuang, Zheng and Cao, Liting and Li, Zemin and Shang, Ying and Ge, Yingying and Hu, Tingting and Sun, Yongchang and Zhao, Wuli and Jin, Rong and Chang, Chun},
  title = {Endogenous Ceramide 24:1 Constrains Th17‐Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202520695}
}
Kostenlos starten →